Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients

Inclusion Criteria

• •1. Age ≥ 18 years
• •2. Patients have voluntarily to join the study and give written informed consent for the study.
• •3. Histologically documented, stage II-IIIA Non-Small Cell Lung Cancer (according to version 9th of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and previously untreated.
• •4. Tumor should be considered resectable before study entry by a multidisciplinary team.
• •5. ECOG Performance Status of 0 or 1
• •6. At least 1 unidimensional measurable lesion meeting Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
• •7. Able to comply with study and follow-up procedures
• •8. Major organ function For regular test results（no blood transfusion within 14 days）：
• •1. Hemoglobin（HB）≥90g/L；
• •2. Absolute neutrophils count（ANC）≥1.5×109/L；
• •3. Blood platelets（PLT）≥100×109/L
• •Biochemical tests results defined as follows:
• •1. Total bilirubin（TBIL）≤1.5 times the upper limit of normal (ULN) ；
• •2. Alanine aminotransferase (ALT) and aspartate aminotransgerase AST≤2.5\*ULN,
• •3. Creatinine（Cr）≤1.5\*ULN or Creatinine Clearance rate (CCr)≥60 ml/min; Coagulation test: INR/APTT within normal limits Doppler ultrasound assessment：left ventricular ejection fraction (LVEF) ≥the lower limit of normal value (50%).
• •9. The patients need to have a forced expiratory volume (FEV1) ≥ 1.2 liters
• •10. Subjects must provide fresh tissues or formalin-fixed tumor tissue samples at or the diagnosis NSCLC for mIF.